{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GM-CSF+%28granulocyte-macrophage+colony-stimulating+factor%2C+sargramostim%29&page=6", "query": { "intervention": "GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 502, "total_pages": 51, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GM-CSF+%28granulocyte-macrophage+colony-stimulating+factor%2C+sargramostim%29&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GM-CSF+%28granulocyte-macrophage+colony-stimulating+factor%2C+sargramostim%29&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T20:48:34.851Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04013672", "title": "Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Glioblastoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "SurVaxM", "type": "DRUG" }, { "name": "Sargramostim", "type": "DRUG" }, { "name": "Montanide ISA 51", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Peereboom", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2020-03-19", "completion_date": "2022-02-16", "has_results": true, "last_update_posted_date": "2024-08-28", "last_synced_at": "2026-10-13T20:48:34.851Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04013672" }, { "nct_id": "NCT00022230", "title": "Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Roger Williams Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2000-01", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2015-05-05", "last_synced_at": "2026-10-13T20:48:34.851Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT00022230" }, { "nct_id": "NCT00546377", "title": "Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "pentostatin", "type": "DRUG" }, { "name": "fluorescence in situ hybridization", "type": "GENETIC" }, { "name": "gene rearrangement analysis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 50, "start_date": "2005-07", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2016-05-12", "last_synced_at": "2026-10-13T20:48:34.851Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00546377" }, { "nct_id": "NCT03400917", "title": "Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Newly Diagnosed Glioblastoma" ], "interventions": [ { "name": "AV-GBM-1", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Aivita Biomedical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 55, "start_date": "2018-06-20", "completion_date": "2023-02", "has_results": false, "last_update_posted_date": "2021-12-16", "last_synced_at": "2026-10-13T20:48:34.851Z", "location_count": 8, "location_summary": "La Jolla, California • Newport Beach, California • Orange, California + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03400917" }, { "nct_id": "NCT00003125", "title": "Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Esophageal Cancer", "Gastric Cancer", "Lung Cancer", "Pancreatic Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "ALVAC-CEA vaccine", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "vaccinia-CEA vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "1998-01", "completion_date": "2004-11", "has_results": false, "last_update_posted_date": "2011-03-24", "last_synced_at": "2026-10-13T20:48:34.851Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003125" }, { "nct_id": "NCT00450008", "title": "Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "GM-CSF", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 9, "start_date": "2006-12", "completion_date": "2008-09", "has_results": false, "last_update_posted_date": "2016-03-17", "last_synced_at": "2026-10-13T20:48:34.851Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450008" }, { "nct_id": "NCT00415857", "title": "Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Peptide Vaccine (PR1 Peptide)", "type": "BIOLOGICAL" }, { "name": "Peginterferon alfa-2b", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2006-12", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2018-08-21", "last_synced_at": "2026-10-13T20:48:34.851Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00415857" }, { "nct_id": "NCT00450619", "title": "153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Samarium Sm 153 lexidronam pentasodium", "type": "RADIATION" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Recombinant vaccinia-TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "Recombinant fowlpox-TRICOM vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 44, "start_date": "2007-02", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2017-01-04", "last_synced_at": "2026-10-13T20:48:34.851Z", "location_count": 3, "location_summary": "Chicago, Illinois • Bethesda, Maryland • New Brunswick, New Jersey", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450619" }, { "nct_id": "NCT00023634", "title": "S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Tumors", "Gastric Cancer", "Ovarian Cancer", "Prostate Cancer" ], "interventions": [ { "name": "KLH", "type": "BIOLOGICAL" }, { "name": "GMCSF", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 14, "start_date": "2001-06", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2015-03-06", "last_synced_at": "2026-10-13T20:48:34.851Z", "location_count": 13, "location_summary": "Bay City, Michigan • Port Huron, Michigan • Bellingham, Washington + 6 more", "locations": [ { "city": "Bay City", "state": "Michigan" }, { "city": "Port Huron", "state": "Michigan" }, { "city": "Bellingham", "state": "Washington" }, { "city": "Bremerton", "state": "Washington" }, { "city": "Mount Vernon", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023634" }, { "nct_id": "NCT00000711", "title": "Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections", "Cytopenias" ], "interventions": [ { "name": "Zidovudine", "type": "DRUG" }, { "name": "Sargramostim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 60, "start_date": null, "completion_date": "1990-05", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-13T20:48:34.851Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000711" } ] }